Home | Welcome to Contract Pharma   
Last Updated Saturday, November 29 2014
Print

IMBRUVICA Capsules Gain Approval in CLL



By Kristin Brooks



Published February 14, 2014
IMBRUVICA (ibrutinib) has been approved by the FDA as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
 
Catalent Pharma Solutions has been contracted by Pharmacyclics to provide drug product capsules of IMBRUVICA for commercial supply from its site in Kansas City, MO.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On